CRISPR repri­or­i­tizes CAR-T pipeline with cuts, ex­pands in­to au­toim­mune dis­ease as US de­ci­sion for exa-cel looms

CRISPR Ther­a­peu­tics is mak­ing sev­er­al changes to its al­lo­gene­ic CAR-T cell ther­a­py pipeline, in­clud­ing pro­gram cuts and mov­ing in­to a new in­di­ca­tion as it awaits …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER